Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Pembrolizumab plus chemo as firstline therapy for NSCLC

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1501
Rating:

Dr Corey Langer - University of Pennsylvania, Philadelphia, USA

Dr Langer speaks with ecancertv at ESMO 2016 about the results from the KEYNOTE-021 trial.

The trial found that the addition of pembrolizumab, a PD-1 antibody, to standard first-line chemotherapy for treatment-naive advanced NSCLC achieved significantly longer progression free survival, a great objective response rate, and a well-tolerated toxicity profile.

Video of the press conference in which Dr Langer announced these results can be watched here.

More details are available in the trial data published in The Lancetand reported on in ecancer news here.

These results complement those presented by Dr Martin Reck, who discussed results from KEYNOTE-024 which recommend pembrolizumab as a firstline therapy for NSCLC patients with high levels of PDL-1 expression.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation